One year results of a phase 1 study of the safety and tolerability of combination therapy using sustained release intravitreal triamcinolone acetonide and ranibizumab for subfoveal neovascular AMD

An update on the pharmacotherapy of neovascular age-related macular degeneration

(2013) K Bailey Freund et al.   EXPERT OPINION ON PHARMACOTHERAPY

Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration

(2013) Brandon G. Busbee et al.   OPHTHALMOLOGY

Bevacizumab and Triamcinolone Acetonide for Choroidal Neovascularization Due to Age-Related Macular Degeneration Unresponsive to Antivascular Endothelial Growth Factors

(2012) Daniele Veritti et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Macular Epiretinal Brachytherapy in Treated Age-related Macular Degeneration

(2012) Pravin U. Dugel et al.   OPHTHALMOLOGY

Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration

(2012) Jeffrey S. Heier et al.   OPHTHALMOLOGY

Clinical Evidence of Intravitreal Triamcinolone Acetonide in the Management of Age-Related Macular Degeneration

(2011) E. M. Becerra et al.   CURRENT DRUG TARGETS

Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration

(2011)   NEW ENGLAND JOURNAL OF MEDICINE